Your browser doesn't support javascript.
loading
Management of excessive gingival display using botulinum toxin type A: a descriptive study.
Andriola, Fernando de Oliveira; Chieza, Gabriela Sperotto; Cavagni, Juliano; Freddo, Angelo Luiz; Corsetti, Adriana.
Afiliação
  • Andriola FO; Department of Oral and Maxillofacial Surgery, Federal University of Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2492, Porto Alegre, RS, Brazil; Department of Oral and Maxillofacial Surgery, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Porto Alegre, RS, Brazil.
  • Chieza GS; School of Dentistry, Federal University of Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2492, Porto Alegre, RS, Brazil.
  • Cavagni J; Periodontology, Federal University of Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2492, Porto Alegre, RS, Brazil.
  • Freddo AL; Department of Oral and Maxillofacial Surgery, Federal University of Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2492, Porto Alegre, RS, Brazil.
  • Corsetti A; Department of Oral and Maxillofacial Surgery, Federal University of Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2492, Porto Alegre, RS, Brazil.
Toxicon ; 196: 56-62, 2021 Jun.
Article em En | MEDLINE | ID: mdl-33794266
Botulinum toxin is a protease used by the bacterium Clostridium botulinum that causes chemical denervation of skeletal muscles, producing a temporary weakening of muscle activity. Despite having a transitory effect, the application of botulinum toxin has been identified as an alternative for correcting an excessive gingival display (EGD). However, studies evaluating the maintenance of long-term results of botulinum toxin remain scarce. This study aimed to evaluate the effectiveness and duration of botulinum toxin type A in the treatment of anterior EGD. Botulinum toxin Type A was applied to 15 patients with EGD. The measurement was performed in triplicate, using a Castro Viejo dry point compass, between the central cervical portion of the upper lateral incisors to the lower portion of the upper lip, bilaterally. The measurements were performed before the application of the toxin and repeated on days 7, 14, 90, 120, and 180 after the procedure. The data were analyzed using repeated-measures ANOVA, followed by a Bonferroni. There was a statistically significant reduction between the measurements performed on the Baseline and seven days after the application of the botulinum toxin. After 180 days, approximately one-quarter of the patients in the sample did not presented EGD. Mild adverse effects were reported by 46.7% of the patients. The use of botulinum toxin type A was effective to treat EGD. After 180 days, it was still possible to observe a significant effect compared to the initial gingival exposure.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxinas Botulínicas Tipo A / Fármacos Neuromusculares Limite: Humans Idioma: En Revista: Toxicon Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Toxinas Botulínicas Tipo A / Fármacos Neuromusculares Limite: Humans Idioma: En Revista: Toxicon Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido